PDF herunterladen
CC BY-NC-ND 4.0 · Journal of Health and Allied Sciences NU 2021; 11(01): 44-46
DOI: 10.1055/s-0040-1718608
Case Report

Case Series of Three Patients with Rifampicin-Induced Thrombocytopenia

Chandramouli M.T
1   Department of Pulmonary Medicine, K.S. Hegde Medical Academy, Mangalore, Karnataka, India
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Life-threatening adverse reactions of antitubercular drugs are uncommon; however, thrombocytopenia is one such rare complication encountered with rifampicin, isoniazid, ethambutol, and pyrazinamide. Rifampicin is the most effective drug and its use in the tuberculosis treatment led to the emergence of modern and effective short-course regimens. I am reporting case series of three patients with pulmonary tuberculosis presented with rifampicin-induced thrombocytopenia.

Keywords

tuberculosis - rifampicin - thrombocytopenia - purpura - antiplatelet antibody


Publikationsverlauf

Artikel online veröffentlicht:
16. Oktober 2020

© 2020. Nitte University (Deemed to be University). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Shinde KM, Pore SM, Bapat TR. Adverse reactions to first-line anti-tuberculous agents in hospitalized patients: pattern, causality, severity and risk factors. Indian J Med Spec. 2013; 4: 1-4
    Google Scholar
  • 2 George JN, Raskob GE, Shah SR. et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998; 129 (11) 886-890
    CrossrefPubMedGoogle Scholar
  • 3 Girling DJ, Hitze KL. Adverse reactions to rifampicin. Bull World Health Organ 1979; 57 (01) 45-49
    PubMedGoogle Scholar
  • 4 Wazny LD, Ariano RE. Evaluation and management of drug-induced thrombocytopenia in the acutely ill patient. Pharmacotherapy 2000; 20 (03) 292-307
    CrossrefPubMedGoogle Scholar
  • 5 Di Berardino L, Perna G, Silvestri LG. Antibodies against rifampin in patients with tuberculosis after discontinuation of daily treatment. Am Rev Respir Dis 1976; 114 (06) 1189-1190
    PubMedGoogle Scholar
  • 6 Ross JD, Horne NW. Drugs used in chemotherapy. In: Horne NW. ed. Modern Drug Treatment of Tuberculosis. 1st Indian ed. New Delhi: Oxford University Press; 1992: 1-17
    Google Scholar
  • 7 Prasad R, Mukerji PK. Rifampicin induced thrombocytopenia. Indian J Tuberc 1989; 36: 44
    Google Scholar
  • 8 Jain VK, Vardhan H, Prakash OM. Pyrazinamide induced thrombocytopenia. Tubercle 1988; 69 (03) 217-218
    CrossrefPubMedGoogle Scholar
  • 9 Mitta A, Curtis BR, Reese JA, George JN. Drug-induced thrombocytopenia: 2019 update of clinical and laboratory data. Am J Hematol 2019; 94 (03) E76-E78
    CrossrefPubMedGoogle Scholar
  • 10 Garg R, Gupta V, Mehra S, Singh R, Prasad R. Rifampicin induced thrombocytopenia. Indian J Tuberc 2007; 54 (02) 94-96
    PubMedGoogle Scholar
  • 11 Blajchman MA, Lowry RC, Pettit JE, Stradling P. Rifampicin-induced immune thrombocytopenia. BMJ 1970; 3 (5713) 24-26
    CrossrefPubMedGoogle Scholar
  • 12 Ackroyd JF. The pathogenesis of thrombocytopenic purpura due to hypersensitivity to sedormid. Clin Sci 1949; 7 (3-4) 249-285
    PubMedGoogle Scholar